

ASX Announcement

23rd September 2026

BCAL introduces Avantect® Multi-Cancer early detection to Australia**Highlights**

- **BCAL introduces Avantect® Multi-Cancer Early Detection (Multi-Cancer) to Australia, commencing with an initial Sydney and Melbourne rollout ahead of broader national expansion.**
- **Avantect® Multi-Cancer is a blood-based test that looks for cancer-associated signals across eight cancers and provides a likely organ-of-origin signal.**
- **The test covers lung, pancreatic, liver, ovarian, gastric, oesophageal, breast and colorectal cancer.**
- **In a case-controlled validation study, Avantect® Multi-Cancer demonstrates overall sensitivity of 56.2% and specificity of 98.4% across all analysed cancers.**
- **Blood samples from Australian patients will be collected through BCAL's clinical networks and initially analysed in Clear Note Health's US laboratory.**
- **Avantect® Multi-Cancer brings BCAL's early detection portfolio to four blood-based tests, with the phased rollout leveraging BCAL's existing national clinical and referral infrastructure ahead of broader release.**

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, has commenced the phased introduction of Avantect® Multi-Cancer in Australia. The Avantect® Multi-Cancer is a blood-based test that detects early cancer-associated signals across eight cancer types and provides a likely organ-of-origin signal, helping provide early, non-invasive detection, not previously available to Australians. The test looks for cancer associated signals across lung, pancreatic, liver, ovarian, gastric, oesophageal, breast and colorectal cancers.

Avantect® Multi-Cancer expands BCAL's early cancer detection portfolio and provides an additional pathway for assessing cancer-associated signals across multiple cancer types. Avantect® Multi-Cancer looks for cancer-associated signals in the blood. If a signal is detected, it indicates the likely organ of origin to help guide further investigation.

In ClearNote Health's case-control validation study, Avantect® Multi-Cancer demonstrated:

- 56.2% overall sensitivity across all analysed cancers
- 98.4% specificity across all analysed cancers

The reported results have been derived from a large case-control study using non-cancer controls, with sensitivity and specificity reported across all cancer stages combined and each of the cancers individually. A sensitivity of 56.2% means a result in which no signal is detected does not exclude cancer. The Multi-Cancer complements established cancer screening programs and other clinically recommended investigations.

Avantect® Multi-Cancer will be accessed through BCAL's existing national clinical, referral and patient-access infrastructure, following a consultation with a General Practitioner or Specialist that requests this service. A phased rollout enables BCAL to build Australian market experience across clinician engagement, patient demand, service delivery, pricing, and access pathways ahead of broader national expansion.

The initial introduction is in Sydney and Melbourne, supported through telehealth and in-person

consultation, with samples processed through ClearNote Health's CLIA-certified and CAP-accredited laboratory in the United States.

BCAL CEO Anne-Louise Arnett said: *"The direction of cancer diagnostics is increasingly toward earlier, less-invasive detection, and blood-based testing has a role to play in that shift. We're pleased to provide Australian patients and the community with another solution to access earlier detection of cancers accessible with a request from a General Practitioner or Specialist."*

"Avantect Multi-Cancer expands our commercial portfolio and provides an opportunity to leverage our existing national infrastructure to build a broader early detection business."

The introduction of Avantect® Multi-Cancer brings BCAL's portfolio to four blood-based early cancer detection services across:

- BREASTESTplus™
- Avantect® Ovarian
- Avantect® Pancreatic
- Avantect® Multi-Cancer

Avantect® Multi-Cancer complements BCAL's existing cancer-specific Avantect® Ovarian and Pancreatic tests and the Company is working to bring the full analysis of this portfolio of tests into its commercial clinical laboratory in Sydney.

For more clinical information regarding how to access Avantect® Multi-Cancer, visit earlydetection.com.au.

This announcement has been approved for release by the Board of BCAL.

ENDS

For further information:

Anne-Louise Arnett
Chief Executive Officer
aarnett@bcaldiagnostics.com

Jayne Shaw
Chair
jshaw@bcaldiagnostics.com

About BCAL Diagnostics

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTESTplus™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

BCAL is headquartered in Sydney, Australia and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.